Regional Content Customized for the United Kingdom (UK)
Stage II Melanoma Treatment Videos
In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses stage II melanoma. The videos address whether to treat, the risks versus benefits of treatment and the differences between the stages IIA, B and C. The content is customised to the UK. This content was recorded in March 2024.
What is stage II melanoma?
Is stage II melanoma at high risk for coming back?
How is stage IIA melanoma treated?
How is stage IIB and C melanoma treated?
How do you weigh the benefits and risks of treatment vs no treatment?
What are the side effects of treatment?
New videos from the experts!
Sequencing of Therapies in Stage IV Melanoma
In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses sequencing strategies for Stage IV melanoma. The videos address strategies for neoadjuvant and adjuvant therapy, first-line and subsequent lines of therapy, single-agent and combination immunotherapy, BRAF-targeted therapy, the management of brain metastases, clinical trials, and management of refractory disease. The videos were recorded on August 9, 2023.
When should neoadjuvant or adjuvant therapy be considered in stage IV disease?
Which immunotherapy should be used for front-line BRAF wild-type patients?
Which combination should be used after progression post PD-1 therapy?
What is the role for BRAF-targeted therapy?
How should strategies be personalised for management of brain metastases?
Strategies for refractory disease?
When should a clinical trial be considered?
New videos from oncology experts!
Immunotherapy Combination Therapy: Current and Emerging Approaches
In this video series, Professor James Larkin, Consultant Medical Oncologist, The Royal Marsden Hospital, discusses current and emerging perspectives on the use of combination immunotherapy in oncology. These videos, developed for the UK audience, discuss the rationale for combination therapy, the data supporting the combination approaches, patient selection for combination immunotherapy versus other options, managing the more complex side effects associated with this approach, as well as new strategies of combined immunotherapy. We hope that this content will be useful for you to select and manage the best immunotherapy regimens for your cancer patients.
Rationale for Combined Immunotherapy
What are the data to support the use of combination immunotherapy
Patient Selection for Combination Immunotherapy
Managing the Complex Adverse Effect Profile of Combination Immunotherapy
Emerging Strategies for Combination Immunotherapy
COVID-19 Vaccine Recommendations for IO Patients
In the following videos, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised to the UK region. This content was recorded on July 7, 2021 and reflects the status of vaccine approvals as of that date. For an updated list of the currently available vaccines approved in the UK, please click here: https://covid19.trackvaccines.org/country/united-kingdom-of-great-britain-and-northern-ireland/
Review of available COVID-19 vaccines
Timing of receipt of vaccines (in general and with haematopoietic cell transplantation and CAR T-cell therapies)
COVID-19 vaccines and ICIs (sequencing, monitoring, and side effects)
Addressing frequently asked questions and myths about COVID-19 vaccines
What to watch for in the future—new COVID-19 vaccine options, impact of variants, and the need for boosters